Home » Newsletters » BioWorld Science

BioWorld Science

July 29, 2021

View Archived Issues

Chengdu Baiyu Pharmaceutical presents new tetrahydrocannabinol derivatives

New RORgammaT agonists identified at Sunshine Lake Pharma

Jiangsu Hansoh Pharmaceutical, Shanghai Hansoh Biomedical patent PD-1/PD-L1 inhibitors

First patients dosed in new studies of Xpovio in melanoma and myelofibrosis

FDA authorizes phase II study of autologous adipose-derived mesenchymal stem cells in MS

Vonafexor meets primary endpoint in the phase IIa LIVIFY study in patients with NASH

New serine-protein kinase ATM inhibitors described by Medshine Discovery

ISIS-814907 well tolerated in first-in-human study in mild Alzheimer's disease patients

MMV-688533 shows excellent single-dose efficacy in P. falciparum-infected mouse model

Selinexor shows antiviral and the anti-inflammatory effects in models of SARS-CoV-2 infection

Phase II study of CETP inhibitor obicetrapib meets primary endpoint

IDMC of phase II study of EscharEx for venous leg ulcers recommends continuation of trial

Targeting the IL-8/CXCR2 axis as a potential therapeutic strategy in prostate cancer

New phase Ib/II trial evaluates pembrolizumab combination therapies in second-line ES-SCLC

Venatorx reports phase I data on beta-lactamase inhibitor VNRX-7145

Arcturus cleared to begin phase II study of ARCT-810 for OTC deficiency

Clarity initiates phase I/IIa theranostic trial of 64/67Cu SAR-bisPSMA in metastatic CRPC

Restoring chondroitin 6-sulfate can rescue age-related memory impairment

Daewoong reports phase IIb topline data on Foistar in mild COVID-19

FDA clears INDs for targeted alpha therapy FPI-1966 and imaging agent FPI-1967

Blueprint Medicines and MD Anderson collaborate on advancing CDK2 inhibitor BLU-222

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...